Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus Price Target from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have earned an average rating of “Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $28.83.

IMNM has been the topic of several recent analyst reports. Piper Sandler dropped their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Finally, Stephens began coverage on Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company.

Insider Activity

In other news, CEO Clay B. Siegall bought 66,057 shares of the stock in a transaction dated Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the acquisition, the chief executive officer now owns 485,693 shares in the company, valued at $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Robert Lechleider purchased 15,805 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average cost of $9.48 per share, with a total value of $149,831.40. Following the completion of the acquisition, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 102,862 shares of company stock worth $978,045. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Arizona State Retirement System raised its stake in shares of Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after acquiring an additional 918 shares during the last quarter. Clear Creek Financial Management LLC raised its holdings in Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after purchasing an additional 4,035 shares during the last quarter. AQR Capital Management LLC lifted its position in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares during the period. Cerity Partners LLC grew its position in shares of Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after buying an additional 5,043 shares during the period. Finally, Quest Partners LLC bought a new stake in shares of Immunome during the second quarter worth approximately $81,000. 44.58% of the stock is owned by institutional investors.

Immunome Stock Performance

Shares of Immunome stock opened at $10.97 on Friday. The firm has a fifty day simple moving average of $12.14 and a 200-day simple moving average of $13.33. The stock has a market capitalization of $684.71 million, a price-to-earnings ratio of -1.35 and a beta of 1.83. Immunome has a 1-year low of $8.97 and a 1-year high of $30.96.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.